An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology

Blood

Volumn 94, Issue 5, 1999, Pages 1517-1536

  Silver, Richard T ^a   Woolf, Steven H ^b   Hehlmann, Rüdiger ^b   Appelbaum, Frederick R ^b   Anderson, James ^b   Bennett, Charles ^b   Goldman, John M ^b   Guilhot, Francois ^b   Kantarjian, Hagop M ^b   Lichtin, Alan E ^b   Talpaz, Moshe ^b   Tura, Sante ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON;

ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEVER; FLU LIKE SYNDROME; HEART MUSCLE FIBROSIS; HUMAN; LIVER FIBROSIS; LUNG FIBROSIS; MALAISE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 13044294682     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK (eds): SEER Cancer Statistics Review, 1973-1991. Tables and Graphs. Bethesda, MD, National Cancer Institute, NIH Pub. No. 94-2789, 1994, p 234
2. German Federal Office of Statistics: Sterbefälle nach Todesursachen in Deutschland. Statistisches Bundesamt, Wiesbaden, Germany, 1995
3. Silver RT: Chronic myeloid leukemia, in Holland JR Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine (ed 4). Baltimore, MD, Williams and Wilkins, 1997, p 2651
4. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR: Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 125:541, 1996
5. Rushing D, Goldman A, Gibbs G, Howe R, Kennedy BJ: Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol 5:307, 1982
6. Bolin RW, Robinson WA, Sutherland J, Hamman RF: Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 50:1683, 1982
7. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Heinze B, Georgii A: Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 82:398, 1993
8. Chronic Myeloid Leukemia Trialists' Collaborative Group: Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616, 1997
9. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle J, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B: The German CML Study Group. Randomized comparison of I interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064, 1994
10. Ohnishi BK, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K: A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906, 1995
11. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU: Leukocyte interferon-induced myeloid cytroreduction in chronic myelogenous leukemia. Blood 62:689, 1983
12. Silver RT, Benn P, Verma RS, Coleman M, Soper L, Gutfriend A: Recombinant gamma-interferon has activity in chronic myeloid leukemia. Am J Clin Oncol 13:49, 1990
13. A in chronic mylogenous leukemia. N Engl J Med 314:1065, 1986
14. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J: Clinical Investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280, 1987
15. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 122:254, 1995
16. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, Arthur DD, Powell B, Gottlieb A, Peterson BA: Prolonged subcutaneous administration of recombinant alpha2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia. Effect on remission duration and survival. Cancer and Leukemia Group B Study 8583. Blood 82:2975, 1993
17. Fernandez-Ranada J, Lavilla E, Odriozola J, Garcia-Larana J, Lozano M, Parody R, Giraldo MP, Carbonell F, Ferro MT, Steegmann JL: Interferon alpha 2a in the treatment of chronic myelogenous leukemia in chronic phase: Results of the Spanish group. Leuk Lymphoma 11:175, 1993 (suppl 1)
18. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M: Interferon-alpha therapy for chronic myelogenous leukemia. Am J Med 99:402, 1995
19. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F: Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 72:642, 1988
20. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani R: Interferon alpha-2b as therapy for patients with Ph'-positive chronic myelogenous leukemia. Eur J Haematol 52:25, 1990 (suppl)
21. Montastruc M, Mahon FX, Faberes C, Marit G, Bilhou-Nabera C, Cony-Makhoul P, Puntous M, Pigneux A, Boiron JM, Bernard P: Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: Results and analysis of predictive factors. Leukemia 9:1997, 1995
22. Italian Cooperative Study Group on Chronic Myeioid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
23. Allan NC, Shepherd PCA, Brackenridge I, Suffolk R: United Kingdom Medical Research Council randomized trial of interferon-alfa in chronic-phase chronic myelogenous leukemia. Semin Hematol 3:20, 1993 (suppl 3)
24. Mahon FX, Montastruc M, Faberes C, Reiffers J: Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha (letter). Blood 84 3592, 1994
25. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome positive patients. Ann Intern Med 114:532, 1991
26. Allan NC, Richards SM, Shepherd PCA, Estey EH, O'Brien S, Beran M, McCredie KB, Gutterman J, Freireich EJ: UK Medical Research Council randomised, multicentre trial of interferon-alpha for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
27. The Benelux CML Study Group: Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia. Blood 91:2713, 1998
28. Kantarjian HM, Talpaz M, Keating MJ, Guerci A, Harousseau JL, Maloisel F, Bouabdalla R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J: Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 68:1201, 1991
29. Kantarjian HM, Talpaz M, Kurzrock, Keating, MJ, McCredie KB, Gutterman J, Freireich EJ: Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematologica 78:70, 1987 (suppl 1)
30. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Quantification of residual disease in chronic myelogenous leukemia patients on inrerferon-alpha therapy by competitive polymerase chain reaction. Blood 87:1549, 1996
31. Henic H, Preudhomme C, Noel M, Lai J, Wetterwald M, Simon M, Fenaux P: Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha (letter). Leukemia 10:185, 1996
32. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M: Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 16: 1526, 1998
33. Hasford J, Baccarani M, Hehlmann R, Ansari H, Tura S, Zuffa E: Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: A comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Blood 87:5384, 1996
34. Sokal JE, Cox EB, Baccarani M, Tora S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F: Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood 63:789, 1984
35. Hasford J, Pfirrman M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans J, Alimena G, Steegmann JL, Ansari H: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90:850, 1998
36. Kantarjian HM, Talpaz M, Kluin-Nelemans, JC, Delannoy A, Louwagie A: Questions raised by the Benelux CML Study Group: Results from the randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon-alpha 2b for chronic myeloid leukemia. Blood 92:2984, 1998
37. Silver RT Benn P, Szatrowski TP, Verma R, Guttfriend A: Infusional cytosinarabinoside (ara-c) and recombinant interferon alpha (r-INF-alpha) for the treatment of chronic myeloid leukemia. Proc Am Soc Clin Oncol 9:209, 1990
38. Guilhot F, Dreyfus B, Brizard A, Huret JL, Tanzer J: Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha-2a and hydroxyurea with or without low-dose cytosine arabinoside. Leuk Lymphoma 4:49, 1991
39. Kantarjian HM, Keating MJ, Estey EH, O'Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M: Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 10:772, 1992
40. Freund M, Hild F, Grote-Metke A, Nowak R, Otremba B, Wörmann B, Koch O, Dohmen M, Kleine H-D, Link H, Hiddeman W, Hinrichs F, Balleisen L, Fonatsch C, Poliwoda H: Combination of chemotherapy and interferon alpha-2b in the treatment of chronic myelogenous leukemia. Semin Hematol 30:11, 1993 (suppl 3)
41. Silver RT, Szatrowski TP, Peterson B, Powell B, Larson R, Stock W, Arthur D, Schiffer C, Bloomfield CD: Combined α-interferon (rINFα-2b) and low dose cytosine arabinoside for Ph(+) chronic phase chronic myeloid leukemia. Blood 88:638a, 1996 (abstr, suppl 1)
42. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J: Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 337:223, 1997
43. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld K, Kolb HJ, Löffler H, Pralle H, Queisser W, Reiter A, Hochhaus A, the German CML-Study Group: Comparative analyses of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and new score. Br J Haematol 97:76, 1997
44. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541, 1998
45. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 11:710, 1983
46. Vial T, Descotes J: Clinical toxicity of the interferons. Drug Safety. 10:115, 1994
47. Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B: Long-term treatment of chronic myelogenous leukemia with different interferons: Results from three studies. Leuk Lymphoma 9:111, 1993
48. Schofield JR, Robinson WA, Murphy JR, Rovira DK: Low doses of interferon-alpha are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736, 1994
49. Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoda H: Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350, 1989
50. Werter M, deWitte JJ, Janssen J, de Pauw B, Haanen C: Recombinant human interferon-alpha induced cytoreduction in chronic myelogenous leukemia: Results of multicenter study. Blut 56:209, 1988
51. Hermann F, Jonas D, Helfrich SG, Lindemann A, Schleiermacher E, Mertelsmann R: Interferon alfa-2c in chronic myelogenous leukemia (CML): Hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma. Blut 61:226, 1990
52. Gralhot F, Ahmad M, Mahon FX, Dreyfus B, Brizard A, Huret JL, Kitzis A, Tanzer J: Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy. Nouv Rev FR Hematol 32:287, 1990
53. Nagler A, Ackerstem A, Barak V, Slavin S: Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a. J Hematother 3:75, 1994
54. Arlin Z, Feldman E, Ahmed T, Mittelman A, Puccio C, Biguzzi S: Intensive chemotherapy with interferon for induction of true remission in chronic phase of chronic mvelogenous leukemia. Cancer Invest 8:303, 1990
55. Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H: Treatment of chronic myelogenous leukemia with interferon alfa-2c: Response rate and toxicity in a Phase II multicenter study. Semin Hematol 30:17, 1993 (suppl 3)
56. Broustet A, Reiffers J, Marit G, Fiere D, Jaubert J, Reynaud J, Pris J, Bernard P, Charrin C, Wen ZQ, Berteas MF, Dastugue N, Parlier Y: Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: Preliminary results of an open French multicentre randomized study. Eur J Cancer 27:518, 1991 (suppl 4)
57. van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, deWitte T, Kolb HJ, Niederwiser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Leukemia Working Party of the European Group for Blood and Marrow Transplantation: Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Parry of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 20:553, 1997
58. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb H-J, McGlave PB, Rassweg JR, Rowlings PA, Sobocinski KA, Horowitz MM, The German CML Study Group: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia (CML). Blood 91:1810, 1998
59. Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witt ON, Champlin R: Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Nad Acad Sci USA 87:563, 1990
60. Delage R, Soiffer RJ, Dear K, Ritz J: Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 78:2759, 1991
61. Snyder DS, Rossi JJ, Wang JL, Sniecinski IJ, Slovak ML, Wallace RB, Forman SJ: Persistence of bcr-abl gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Transplantation 51:1033, 1991
62. Lange W, Kerkert R, Finke J, Ragoczy U, Siegert W, Mertelsmann R, Dolken G: Apparent decrease and elimination of BCR/ABL mRNA-expressing residual cells in patients with chronic myelogenous leukemia after allogeneic bone marrow transplantation. Ann Hematol 63:189, 1991
63. Okamoto R, Harano H, Matsuzaki M, Motomura S, Maruta A, Kodama F, Mohri H, Okubo T: Predicting relapse of chronic myelogenous leukemia after alllogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting. Am J Clin Pathol 104:510, 1995
64. Preudhomme C, Wattel E, Lai JL, Henic N, Meyer L, Noel MP, Cosson A, Jouet JP, Fenaux P: Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: A report on 38 consecutive cases. Leuk Lymphoma 18:265, 1995
65. Costello RT, Kirk J, Gaben J: Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: A comparative study. Leuk Lymphoma 20:239, 1996
66. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86:3118, 1995
67. Bose S, DeIninger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362, 1998
68. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg H, Doney KC, Fisher LD, Hansen JA: Marrow transplantation for chronic myelogenous leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
69. Nevill TJ, Barnett MJ, Klingeman HG, Reece DE, Shepherd JD, Phillips GL: Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 9:1224, 1991
70. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R: Methotrexate and cyclosporine versus cyclosporine along for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 73:1729, 1989
71. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155, 1986
72. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlave PB: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion Ann Intern Med 108:806, 1988
73. Sullivan KM, Weiden PL, Storb R Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C: Influence of acute and chronic graft-versus-host disease in relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment for acute and chronic leukemia. Blood 73:1720, 1989
74. Horowitz MM, Gage RP, Sondel DM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B: Graft versus leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
75. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GW, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225, 1993
76. von Bueltzingsloewen A, Belanger R, Perreault C, Bonny Y, Roy DC, Lalonde Y, Boileau J, Kassis J, Lavallee R, Lacombe M: Acute giaft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies. Blood 81:849, 1993
77. Lishner M, Patterson B, Kandel R, Fyles G, Curtis JE, Meharchand J, Minden MD, Messner HA: Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 65:473, 1990
78. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF Jr, Boice JD Jr: Solid cancers after bone marrow transplantation. N Engl J Med 336:897, 1997
79. Deeg H, Flournoy N, Sullivan KM, Sheehan K, Buckner CD, Sanders JE, Storb R, Witherspoon RP, Thomas ED: Cataracts after total body irradiation and marrow transplantation: A sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys 10:957, 1984
80. Goldman J, Apperley JF, Jones L, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG: Bone marrow transplantation for patients with chronic myeloid leukemia N Engl J Med 314:202, 1986
81. McGlave P, Arthur D, Haake R, Hurd D, Miller W, Vercellotti G, Weisdorf D, Kim T, Ramsay N, Kersey J: Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J Clin Oncol 5:1033, 1987
82. Wagner JE, Zahurak M, Piantadosi S, Geller RB, Vogelsang GB, Wingard JR, Saral R, Griffin C, Shah N, Zehnbauer BA: Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: Evaluation of risks and benefits. J CUn Oncol 10:779, 1992
83. Brodsky I, Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, Concannon AJ, Avalos BR, Tutschka P: Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): An update. Semin Oncol 20:27, 1993 (suppl 4)
84. Galimberti M, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Giardini C, Gaziev D, Erer B, Ripalti M, Rapa S: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Bone Marrow Transplant 13:197, 1994
85. Appelbaum FR, Clift R, Radich J, Anasetti C, Buckner CD: Bone marrow transplantation for chronic myelogenous leukemia. Semin Oncol 22:405, 1995
86. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235, 1993
87. Devergie A, Reiffers J, Vernant JP, Herve P, Guyotat D, Maraninchi D, Rio B, Michallet M, Jouet JP, Milpied N, Leblond V, Pico J, Attal M, Belanger C, Bordigoni P, Leporrier M, Ifrah N, Gratecos N, Bergerat JP, Legros M, Frappaz D, Gluckman E: Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: Factors associated with relapse. Bone Marrow Transplant 5:379, 1990
88. McGlave P, Bartsch G, Anasetti C, Ash R, Beany P, Gajewski J, Kernan NA: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543, 1993
89. Perkins HA, Kollman C, Howe CWS: Unrelated-donor marrow transplants: The experience of the National Marrow Donor Program. Clin Transpl 295, 1994
90. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti F: Bone marrow transplants from unrelated donor for patients with chronic myeloid leukemia. N Engl J Med 338:962, 1998
91. Sasazuki T, Juju T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, Yoshida T, Kimura A, Akaza T, Kamikawaji N, Kodera Y, Takaku F, for the Japan Marrow Donor Program: Effect of matching of class I HLA allelles on clinical outcome after transplantation of hematopoietic stem cells for an unrelated donor. N Engl J Med 339:1177, 1998
92. Aschan J, Ringden O, Sundberg B, Klaesson S, Ljungman P, Lonnqvist B: Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporine or monotherapy for the prevention of graft-versus-host disease. Eur J Haematol 50:269, 1993
93. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B, Schaefer UW: Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 85:2981, 1995
94. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Camplin RE: Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 11:1055, 1993
95. Zuffa E, Bandini G, Bonini A, Santucci MA, Martinelli G, Rosti G, Testoni N, Zaccaria A, Tura S: Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 83:231, 1998
96. Tomas JF, Lopez-Lorenzo JL, Requena MJ, Aguilar R, Steegmann JL, Camara R, Alegre A, Arranz R, Figuera A, Fernandez-Ranada JM: Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 22:47, 1998
97. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM, Woolfrey A, Anasetti C: Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 92:394, 1998
98. Woolf SH: Shared decision-making: The case for the letting patients decide which choice is best. J Fam Pract 45:205, 1997
99. Kurschel E, Metz-Kurschel U, Niederle N, Aulbert E: Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail 13:87, 1991
100. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, Seeber S, Niederle N: Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65:70, 1992
101. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M: Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13:2401, 1995
102. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WT: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 77:1660, 1991
103. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner S, Rimm AA: Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet 1:665, 1984
104. Snyder DS, Findley DO, Forman SJ, Nademanee AP, O'Donnell MR, Schmidt GM, Bierman PJ, Fahey JL, Krance RA, Sniecinski IJ: Fractionated total body irradiation and high dose cyclophosphamide: A preparative regimen for bone marrow transplantation for patients with hematologic malignancies in first complete remission. Blut 57:7, 1988
105. Snyder DS, Negrin RS, O'Donnell MR, Chao N, Amylon MD, Long GD, Nademanee AP, Stein AS, Parker PM, Smith EP: Fractionated total-body irradiation high-dose etoposide as a preparatory regimen tor bone marrow transplantation tor 94 patients with chronic myelogenous leukemia in chronic phase. Blood 84:1672, 1994
106. Selby GB, Saez RA, Epstein RB, Slease RB, Confer DL: Allogeneic bone marrow transplantation: Experience with 92 patients. J Okla State Med Assoc 86:599, 1993
107. De Witte T, Schattenberg A, Preijers F, Raymakers R, Muus P, Wessels J: Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation. Bone Marrow Transplant 12:S2, 1993 (suppl 3)
108. Thomas ED, Clift RA: Indications for marrow transplantation in chronic myelogenous leukemia. Blood 73:861, 1989